However, besides these encouraging results, the use of PARPi remains clinically relegated to few cancer types and their administration relays mainly on patient stratification based on “BRCAness” [18], obtained by gene mutation analysis of BRCA1/2 and its modulators, without considering the actual PARP activities. This evidence concerns the gene PARP1 and cancer.